Published in

Wiley, Proteomics, 12(14), p. 1472-1479, 2014

DOI: 10.1002/pmic.201300485

Links

Tools

Export citation

Search in Google Scholar

The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles

This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

ERBB2/HER2 amplification activates signaling cascades that lead to a tumor cell phenotype. However, despite its remarkable importance in oncology, the consequences of HER2 amplification over the extracellular vesicles (EVs) content have not yet been investigated. Here we isolated EVs secreted by HB4a, a mammary luminal epithelial cell-line and C5.2, its HER2-overexpressing clone. We isolated two EV-sets (20K and 100K) by ultracentrifugation and used electron microscopy and Nanoparticle Tracking Analysis for their morphological characterization. We employed GeLC-MS/MS combined with isotope-coded protein labeling to evaluate cell-derived proteins and LC-MS/MS/label-free spectral-counting to quantify the EVs-proteome. We found higher HER2 levels in both C5.2-derived EVs when compared with C5.2 cells, suggesting its preferential shuttling. Proteins capable of inducing malignant transformation are enriched in both C5.2 EV-subsets, including two HER2-related proteins involved in cell motility and invasion, cofilin and CD44. MetaCore™ analysis indicated an enrichment of cell-adhesion and cytoskeleton-remodeling pathways in C5.2-EVs, as well as proteins related to HER2 signaling, such as the sphingosine-1-phosphate (S1P) pathway. Together our data indicates that in terms of protein content, distinct vesicle sets reinforce and complement each other. Our results also suggest that HER2-upregulated proteins from EVs may be relevant for cellular malignancy and can be potential biomarkers for HER2(+) cancer patients. This article is protected by copyright. All rights reserved.